Umbilical Cord PRP vs. Autologous PRP for the Treatment of Hip Osteoarthritis
Authors:
Open Access
- 2 August 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (15) , 4505
Abstract
Umbilical cord platelet-rich plasma (C-PRP) has more growth factors and anti-inflammatory molecules compared with autologous PRP (A-PRP) derived from peripheral blood. The aim of this study was to compare intra-articular C-PRP or A-PRP injections in terms of safety and clinical efficacy for the treatment of patients with hip osteoarthritis (OA). This study investigated the results of 100 patients with hip OA treated with three weekly ultrasound-guided injections of either C-PRP or A-PRP. Clinical evaluations were performed before the treatment and after two, six, and twelve months with the HHS, WOMAC, and VAS scores. No major adverse events were recorded. Overall, the improvement was limited with both treatments. Significant improvements in VAS (p = 0.031) and HHS (p = 0.011) were documented at two months for C-PRP. Patients with a low OA grade (Tonnis 1-2) showed a significantly higher HHS improvement with C-PRP than A-PRP at twelve months (p = 0.049). C-PRP injections are safe but offered only a short-term clinical improvement. The comparative analysis did not demonstrate benefits compared with A-PRP in the overall population, but the results are influenced by OA severity, with C-PRP showing more benefits when advanced OA cases were excluded. Further studies are needed to confirm the most suitable indications and potential of this biological injective approach.Keywords
Funding Information
- Italian Ministry of Health (RCR-2021-23671217)
This publication has 49 references indexed in Scilit:
- The Anti-inflammatory and Matrix Restorative Mechanisms of Platelet-Rich Plasma in OsteoarthritisThe American Journal of Sports Medicine, 2013
- Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: a reviewOsteoarthritis and Cartilage, 2013
- Plasma‐mediated immune suppression: a neonatal perspectivePediatric Allergy and Immunology, 2012
- Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservationBiomaterials, 2012
- What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patientsBMJ Open, 2012
- Platelet-Rich Plasma Releasate Inhibits Inflammatory Processes in Osteoarthritic ChondrocytesThe American Journal of Sports Medicine, 2011
- Platelet‐Rich Plasma Intra‐Articular Injection Versus Hyaluronic Acid Viscosupplementation as Treatments for Cartilage Pathology: From Early Degeneration to OsteoarthritisArthroscopy, 2011
- Proteomic and Phospho-Proteomic Profile of Human Platelets in Basal, Resting State: Insights into Integrin SignalingPLOS ONE, 2009
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IIArthritis & Rheumatism, 2007
- Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet countJournal of Cranio-Maxillofacial Surgery, 2002